MIVOCELL
Live / Applied — Second extension granted (statement of use) (as of 24 Feb 2026)
What this means for you
Not registered yet, but its 05 Sept 2024 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 98734979
- Mark type
- Stylized text
- Filed
- 05 Sept 2024
- Published for opposition
- 18 Feb 2025
- Attorney of record
- Lisa Greenwald-Swire
Goods and services
- Class 005 — Pharmaceuticals: Therapeutic pharmaceuticals for the treatment of autoimmune diseases and cancer; therapeutic pharmaceuticals and cell therapy products in the nature of cells for medical or clinical use for the treatment of autoimmune disease and cancer; cell therapy products, namely, genetically engineered immune cells for medical or clinical use for the treatment of autoimmune disease and cancer; pharmaceutical products for the prevention and treatment of cancer; pharmaceutical preparations and substances for the treatment of oncological and immune system related diseases and disorders
Owner
- Kyverna Therapeutics, Inc., Emeryville, CA, US
- Kyverna Therapeutics, Inc., Emeryville, CA, US
Prosecution history
- 25 Feb 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 24 Feb 2026 — SOU EXTENSION 2 GRANTED
- 24 Feb 2026 — SOU EXTENSION 2 FILED
- 24 Feb 2026 — SOU TEAS EXTENSION RECEIVED
- 11 Sept 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 10 Sept 2025 — SOU EXTENSION 1 GRANTED
- 10 Sept 2025 — SOU EXTENSION 1 FILED
- 10 Sept 2025 — SOU TEAS EXTENSION RECEIVED
- 15 Apr 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 18 Feb 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 18 Feb 2025 — PUBLISHED FOR OPPOSITION
- 12 Feb 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 27 Jan 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 15 Jan 2025 — ASSIGNED TO EXAMINER
- 05 Sept 2024 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED